Infermedica, the Polish health tech start-up, will expand its US investments, thanks to the funding gained in a recent Series B financing round. HBI talks with Miłosz Wiciński, Business Development Executive at Infermedica, to learn more.
As Germany-based healthcare conglomerate Fresenius looks to simplify the group's structure, selling off non-core parts of a business which currently spans hospitals, dialysis, pharma, rehabilitation and more, it is building a $2.4bn new business partnership in the US. We speak to an EU-based source familiar with Fresenius to put this all in context.
Smart reha, medical malls, how to best deploy new medtech, Fresenius Vamed veterans both, Dagmar and Roland are full of ideas on how to best build and run health care service models from acute hospitals to rehab and outpatient. Two and a half years ago they quit the mothership to set up Aquila which now employs 45 and runs projects in China, SE Asia, Austria, Germany and the Czech Rep.
Clinisys claims to have created the world’s largest player in lab information management and lab order comms and results software with a three-way merger which creates a platform across diagnostics and environmental tests. So how does CEO, Michael Simpson, see software changing the sector over the next 3-5 years? And what does an independent consultant with many years experience in the field think about the sector and its growth?
Spain-based fertility provider Eugin Group, part of Germany-based hospital group Fresenius Helios, has acquired a majority stake in a US-based fertility centre.
The more you look at the Babylon SPAC deal, the more black box it looks. The sheer complexity of the US insurance system makes it impossible for investors to assess its prospects with any accuracy. And then there is the question of the $230m sale of shares made by "certain accredited investors". How much of this went to Babylon founder Ali Parsa?
Ali Parsa, the founder of Babylon Health, is now a paper billionaire with control of a business with an enterprise value of $3.6bn with an additional $575m in gross proceeds, following its merger with special acquisition vehicle Alkuri. The nearly 90% of the SPAC shareholders who chose to sell before the shares started trading may be kicking themselves - the shares peaked at $16 on October 26, though as of the time of writing are sitting at $10.82, up from the initial opening price of 10$ on October 22.
Scotland will become the first country in the world to offer digital therapeutics for insomnia and anxiety for free at a national level, after NHS Scotland announced on October 13 that it has contracted with digital therapeutics group Big Health to make its two apps available to all five million Scottish adults. Big Health’s UK Director, Dr. Charlotte Lee, tells HBI the company plans to retain its focus on insomnia and anxiety as these areas are key to good overall mental health.
A pioneering blood test which helps clinicians diagnose bipolar disorder will come to market shortly. HBI catches up with Alexandra Prieux, CEO at France-based ALCEDIAG, which should be first to market with the first of what could be a series of tests.
Babylon says it will complete its SPAC merger in mid-October, with the company reporting five-fold revenue growth in the first half. New American contracts have proved extremely lucrative for the UK-based telehealth company - but it expects to lose money for another two years.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.